Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

First Posted Date
2019-01-17
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT03808610
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

First Posted Date
2019-01-11
Last Posted Date
2024-04-19
Lead Sponsor
TG Therapeutics, Inc.
Target Recruit Count
277
Registration Number
NCT03801525
Locations
🇺🇸

TG Therapeutics Investigational Trial Site, Seattle, Washington, United States

🇺🇸

TG Therapeutics Investigational Site, Louisville, Kentucky, United States

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

First Posted Date
2019-01-09
Last Posted Date
2021-12-07
Lead Sponsor
AbbVie
Target Recruit Count
9
Registration Number
NCT03797261
Locations
🇺🇸

USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States

🇺🇸

Duplicate_Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States

🇦🇺

Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia

and more 14 locations

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

First Posted Date
2018-12-24
Last Posted Date
2019-08-28
Lead Sponsor
AbbVie
Registration Number
NCT03785184
Locations
🇦🇺

St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia

🇨🇦

Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada

🇦🇺

Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia

and more 19 locations

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

First Posted Date
2018-12-07
Last Posted Date
2024-12-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1000
Registration Number
NCT03768063
Locations
🇺🇸

Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States

🇺🇸

HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States

and more 199 locations

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage a

Phase 2
Active, not recruiting
Conditions
Chronic Lymphoid Leukemia
Interventions
Drug: Venetoclax
First Posted Date
2018-12-06
Last Posted Date
2024-10-29
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
82
Registration Number
NCT03766763
Locations
🇫🇷

Chu Amiens, Amiens, France

🇫🇷

Chu Angers, Angers, France

🇫🇷

Ch Annecy, Annecy, France

and more 20 locations

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

First Posted Date
2018-11-28
Last Posted Date
2021-02-02
Lead Sponsor
Grupo Cooperativo de Hemopatías Malignas
Target Recruit Count
3
Registration Number
NCT03755947
Locations
🇲🇽

Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

First Posted Date
2018-11-23
Last Posted Date
2023-10-16
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
10
Registration Number
NCT03751436
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

First Posted Date
2018-11-14
Last Posted Date
2024-10-02
Lead Sponsor
Loxo Oncology, Inc.
Target Recruit Count
860
Registration Number
NCT03740529
Locations
🇺🇸

University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

Ohio State University Hospital, Columbus, Ohio, United States

🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 53 locations

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

First Posted Date
2018-11-14
Last Posted Date
2024-01-25
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
Target Recruit Count
5
Registration Number
NCT03739554
Locations
🇺🇸

Investigational Site, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy